Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat

Brain Research Bulletin

Volumn 85, Issue 3-4, 2011, Pages 158-168

  Kumar, Anil ^a   Prakash, Atish ^a   Pahwa, Deeksha ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Galantamine; Kainic acid; Mitochondria; Oxidative damage; Rofecoxib

Indexed keywords

ACETYLCHOLINESTERASE; CAFFEIC ACID; CYCLOOXYGENASE 2 INHIBITOR; GALANTAMINE; KAINIC ACID; LIPOXYGENASE INHIBITOR; MITOCHONDRIAL ENZYME; NITRITE; ROFECOXIB; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG POTENCY; HIPPOCAMPUS; LIPID PEROXIDATION; LOCOMOTION; MAZE TEST; MEMORY; MEMORY CONSOLIDATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PERFORMANCE; PRIORITY JOURNAL; RAT;

ACETYLCHOLINESTERASE; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CAFFEIC ACIDS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; GALANTAMINE; GLUTATHIONE; HIPPOCAMPUS; KAINIC ACID; LACTONES; LIPID PEROXIDATION; MAZE LEARNING; MITOCHONDRIA; MOTOR ACTIVITY; NADH DEHYDROGENASE; NITRITES; NOOTROPIC AGENTS; RATS; RATS, WISTAR; SUCCINATE DEHYDROGENASE; SULFONES; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79957864085     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.03.010     Document Type: Article

References (60)

1. + channels by galantamine can also contribute to the potentiation of catecholamine secretion from chromaffin cells. Eur. J. Pharmacol. 2006, 548:45-52.
2. Arias E., Alés E., Gabilan N.H., Cano-Abad M.F., Villarroya M., Garcia A.G., Lopez M.G. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004, 46:103-114.
3. Bai F., Zhang Z., Watson D.R., Yu H., Shi Y., Yuan Y., Zang Y., Zhu C., Qian Y. Abnormal functional connectivity of hippocampus during episodic memory retrieval processing network in amnestic mild cognitive impairment. Biol. Psychiatry 2009, 65:951-958.
4. Baik E.J., Kim E.J., Lee S.H., Moon C.-H. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 1999, 843:118-129.
5. Barnes C.A., Meltzer J., Houston F., Orr G., McGann K., Wenk G.L. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000, 99:17-23.
6. Benetti F., Mello P.B., Bonini J.S., Monteiro S., Cammarota M., Izquierdo I. Early postnatal maternal deprivation in rats induces memory deficits in adult life that can be reversed by donepezil and galantamine. Int. J. Dev. Neurosci. 2009, 27:59-64.
7. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 1999, 73:1127-1137.
8. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B.L., Pozzan T., Volterra A. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998, 391:281-285.
9. Bishnoi M., Patil C.S., Kumar A., Kulkarni S.K. Protective effects of nimesulide (COX Inhibitor), AKBA (5-LOX Inhibitor), and their combination in aging-associated abnormalities in mice. Methods Find Exp. Clin. Pharmacol. 2005, 7:465-470.
10. Court J., Martin-Ruiz C., Piggott M., Spurden D., Griffiths M., Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol. Psychiatry 2001, 9:175-184.
11. Coyle J.T., Geerts H., Sorra K., Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J. Alzheimer's Dis. 2007, 11:491-507.
12. Dani J.A. Overview of nicotinic receptors and their roles in the central nervous system. Biol. Psychiatry 2001, 49:166-174.
13. Dhir A., Naidu P.S., Kulkarni S.K. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure 2007, 16:691-697.
14. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82:70-77.
15. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-90.
16. Ezoulin M.J.M., Ombetta J.-E., Dutertre-Catella H., Warnet J.-M., Massicot F. Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells. Neurotoxicology 2008, 29:270-277.
17. Finsterer J. Cognitive decline as a manifestation of mitochondrial disorders (mitochondrial dementia). J. Neurol. Sci. 2008, 272:20-33.
18. Fragkouli A., Hearn C., Errington M., Cooke S., Grigoriou M., Bliss T., Stylianopoulou F., Pachnis V. Loss of forebrain cholinergic neurons and impairment in spatial learning and memory in LHX7-deficient mice. Eur. J. Neurosci. 2005, 21:2923-2938.
19. Francis P.T., Nordberg A., Arnold S.E. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. Trends Pharmacol. Sci. 2005, 26:104-111.
20. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J. Neural Transm. 2002, 62(Suppl.):181-187.
21. Gold P.E. Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol. Learn. Mem. 2003, 80:194-210.
22. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 1949, 177:751-766.
23. Green L.C., Wagner D.A., Glagowski J. Analysis of nitrate, nitrite and (15N) nitrate in biological fluids. Anal. Biochem. 1982, 126:131-138.
24. Greenfield S.A., Vaux D.J. Parkinson's disease, Alzheimer's disease and motor neurone disease: identifying a common mechanism. Neuroscience 2002, 113:485-492.
25. Guan Z.Z., Zhang X., Ravid R., Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J. Neurochem. 2000, 74:237-243.
26. Ji X., Li C., Luc Y., Chena Y., Guoa L. Post-ischemic continuous administration of galantamine attenuates cognitive deficits and hippocampal neurons loss after transient global ischemia in gerbils. Neurosci. Lett. 2007, 416:92-95.
27. Kalonia H., Kumar P., Kumar A., Nehru B. Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. Neurosci. Bull. 2009, 25:343-352.
28. King T.E. Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol. 1967, 10:322-331.
29. King T.E., Howard R.L. Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol. 1967, 10:275-294.
30. Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch. Biochem. Biophys. 1978, 186:189-195.
31. Kozak R., Martinez V., Young D., Brown H., Bruno J.P., Sarter M. Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing rats. Neuropsychopharmacology 2007, 32:2074-2086.
32. Kumar A., Garg R. Possible nitric oxide modulation in the protective effect of trazodone against sleep deprivation-induced anxiety like behavior and oxidative damage in mice. Int. J. Health Res. 2008, 1:151-162.
33. Kumar M.H.V., Gupta Y.K. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol. Biochem. Behav. 2002, 73:565-571.
34. Kume T., Sugimoto M., Takada Y., Yamaguchi T., Yonezawa A., Katsuki H., Sugimoto H., Akaike A. Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur. J. Pharmacol. 2005, 527:77-85.
35. Kunz T., Marklund N., Hillered L., Oliw E.H. Assessment of the effects of the cyclooxygenase-2 inhibitor rofecoxib on visuospatial learning and hippocampal cell death following kainate-induced seizures in the rat. Cogn. Brain Res. 2005, 25:826-832.
36. Liu Y., Peterson D.A., Kimura H., Schubert D. Mechanisms of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide (MTT) reduction. J. Neurochem. 1997, 69:581-593.
37. Lorrio S., Sobrado M., Arias E., Roda J.M., Garcia A.G., Lopez M.G. Galantamine post ischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J. Pharmacol. Exp. Ther. 2007, 322:591-599.
38. Maelicke A., Schrattenholz A., Samochocki M., Radina M., Albuquerque E.X. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav. Brain Res. 2000, 113:199-206.
39. Mohapel P., Leanza G., Kokaia M., Lindvall O. Forebrain acetylcholine regulates adult hippocampal neurogenesis and learning. Neurobiol. Aging 2005, 26:939-946.
40. Moreira P.I., Zhu X., Liu Q., Honda K., Siedlak S., Harris P.L., Smith M.A., Perry G. Compensatory responses induced by oxidative stress in Alzheimer disease. Biol. Res. 2006, 39:7-13.
41. Mulder J., Harkany T., Czollner K., Cremers T.I., Keijser J.N., Nyakas C., Luiten P.G. Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum. Behav. Brain Res. 2005, 163:33-41.
42. C. Nyakas, I. Granic, L.G. Halmy, P. Banerjee, P.G. Luiten, The basal forebrain cholinergic system in ageing and dementia. rescuing cholinergic neurons from neurotoxic amyloid-beta42 with memantine, Behav. Brain Res. (2010), in press, doi:10.1016/j.bbr.2010.05.033.
43. Pan Y.-P., Xu X.-H., Wang X.-L. Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons. Neurosci. Lett. 2002, 336:37-40.
44. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 2000, 61:75-111.
45. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, San Diego. 6th ed.
46. Prado V.F., Martins-Silva C., Castro B.M., Lima R.F., Barros D.M., Amaral E., Ramsey A.J., Sotnikova T.D., Ramirez M.R., Kim H.-G., Rossato J.I., Koenen J., Quan H., Cota V.R., Moraes M.F.D., Gomez M.V., Guatimosin C., Westel W.C., Kushmerick C., Pereira G.S., Gainetdinov R.R., Izquierdo I., Caron M.G., Prado M. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron 2006, 51:601-612.
47. Racchi M., Mazzucchelli M., Porrello E., Lanni C., Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol. Res. 2004, 50:441-451.
48. Rezvani A.H., Levin E.D. Cognitive effects of nicotine. Biol. Psychiatry 2001, 49:258-267.
49. Saéz-Valero J., Carmen G., Valenti C. Acetylcholinesterase activation in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. Neurosci. Lett. 2003, 348:123-125.
50. Samochocki M., Hoffle A., Fehrenbacher A., Jostock R., Ludwig J., Christner C., Radina M., Zerlin M., Ullmer C., Pereira E.F., Lubbert H., Albuquerque E.X., Maelicke A. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 2003, 305:1024-1036.
51. Sarter M., Bruno J.P. Developmental origins of the age-related decline in cortical cholinergic function and associated cognitive abilities. Neurobiol. Aging 2004, 25:1127-1139.
52. Srivastava N., Seth K., Srivastava N., Khanna V.K., Agrawal A.K. Functional restoration using basic fibroblast growth factor (bFGF) infusion in kainic acid induced cognitive dysfunction in rat: neurobehavioural and neurochemical studies. Neurochem. Res. 2008, 33:1169-1177.
53. Tayebati S.K., Di Tullio M.A., Tomassoni D., Amenta F. Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats. J. Neurol. Sci. 2009, 283:187-194.
54. Traykova M., Traykov T., Hadjimitov V., Krikorian K., Bojadgiev N. Antioxidant properties of galantamine hydrobromide. Z. Naturforsch. 2003, 58:361-365.
55. Wang Q., Yu S., Simonyi A., Sun G.Y., Sun A.Y. Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol. Neurobiol. 2005, 31:3-16.
56. Wills E.D. Mechanism of lipid peroxide formation in animal tissues. Biochem. J. 1966, 99:667-676.
57. Woodruff-Pak D., Lander C., Geerts H. Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002, 8:405-426.
58. Zahler W.L., Cleland W.W. A specific and sensitive assay for disulfides. J. Biol. Chem. 1968, 243:716-719.
59. Wu D., Meydani S.N. Mechanism of age-associated up-regulation in macrophage PGE2 synthesis. Brain Behav. Immun. 2004, 18:487-494.
60. Zhang L., Zhou F.M., Dani J.A. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol. Pharmacol. 2004, 66:538-544.